Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis
Nutrients · 11.08.2026 · 18 (16) · 2623
DOI: 10.3390/nu18162623 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Nutrients, online erschienen am 11.08.2026. Verfasst von Md Towhidul Islam Tarun und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 7…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cyclopentane Monoterpenes, Olive Oil, Phenols. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edward Via College of Osteopathic Medicine, VCOM FY25 Delta Collaborative Research Program.
Abstract (Originalsprache)
Background/Objectives: Colorectal cancer (CRC) is the second most common cancer-causing death in the United States. The Mediterranean diet, rich in extra-virgin olive oil (EVOO), is associated with a lower risk of colorectal cancer (CRC). Earlier studies reported S-(−)-oleocanthal (OC), the major EVOO phenolic, to be effective in CRC progression and recurrence suppression in a subcutaneous xenograft model by targeting the SMYD2–EZH2/c-MET signaling axis and favorably modulating gut microbiota (GM). However, lead validation in an orthotopically xenografted model that mimics the tumor microenvironment is yet to be achieved. The GM contribution to OC anti-CRC activity remains unknown.
Methods
We used an orthotopic intra-cecally xenografted nude mouse model to validate OC anti-KRAS-mutant CRC activity and assessed the contribution of OC GM modulation to this activity using an oral antibiotic depletion strategy.
Results
Daily oral 10 mg/kg OC impressively suppressed KRASG13D-mutant CRC HCT-116-Luc progression and metastasis more effectively than intraperitoneal administration 3×/week. By contrast, GM depletion with a broad-spectrum antibiotics cocktail (ABC) partially attenuated this activity, suggesting GM contribution to OC anti-CRC activity. Thus, fecal microbiota transplantation (FMT) was conducted using fresh daily oral fecal GM treatments collected from 20 mg/kg OC-dosed nude mouse donors. A week before FMT dosing, orthotopic HCT-116-Luc tumor-bearing recipient mice were subjected to GM depletion using daily oral ABC dosing. Recipient mice treated with FMT from OC-treated donors exhibited dramatic >99% reductions in primary and near-complete suppression of multi-organ metastatic tumor burden versus FMT controls.
Conclusions
Collectively, oral OC is validated as an effective anti-KRASG13D-mutant CRC lead. Future clinical trials can validate its anti-CRC potential in a human model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
- Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
ORCID-Profile: Md Towhidul Islam Tarun, Khalid A El Sayed
Förderung
- Edward Via College of Osteopathic Medicine
- VCOM FY25 Delta Collaborative Research Program
Zitieren
APA
Tarun, M. T. I., Ebrahim, H. Y., & El Sayed, K. A. (2026). Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis. Nutrients, 18(16), 2623. https://doi.org/10.3390/nu18162623
Vancouver
Tarun MTI, Ebrahim HY, El Sayed KA. Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis. Nutrients. 2026;18(16):2623. doi:10.3390/nu18162623
BibTeX
@article{Tarun2026,
author = {Tarun, Md Towhidul Islam and Ebrahim, Hassan Y and El Sayed, Khalid A},
title = {Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {16},
pages = {2623},
doi = {10.3390/nu18162623}
}
EUVIMED